EDWARDS LIFESCIENCES CORP

ISIN: **US28176E1082** WKN: 28176E108 Asset Class: Stock

Company

Edwards

2024/08/15 22:00:02

Price 68.12 USD

Difference

2.44%(1.62)

Contact Details

EDWARDS

Tel: +1-949-250-2500 LIFESCIENCES CORP.


1 Edwards Way

Web: http://www.edwards.com

Fax: +

E-mail: 92614 Irvine

customerservice_us@edwards.com



Company Profile

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	2023 Assets Liabilities and equity		2022 Assets Liabilities and equity		2021 Assets Liabilities and equity	
Financial figures							
Current assets	4,035,700,000		3,095,800,000		3,180,700,000		
Common stock capital		650,500,000		646,300,000		642,000,000	
Fixed assets	5,327,500,000		5,196,700,000		5,321,900,000		
Equity capital of a company		6,719,400,000		5,806,700,000		5,835,900,000	
Cash and cash equivalents	1,147,300,000		769,500,000		864,300,000		
Accrued liabilities		433,500,000		410,500,000		450,300,000	
Other assets	-		-		-		
Current liabilities		1,195,400,000		1,022,400,000		1,032,300,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		1,448,400,000		1,463,400,000		1,634,400,000	
Different income		-		-		-	
Other liabilities		344,900,000		387,100,000		519,300,000	
Total assets	9,363,200,000	9,363,200,000	8,292,500,000	8,292,500,000	8,502,600,000	8,502,600,000	

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	19,800	17,300	15,700
Equity ratio	72.51%	70.02%	68.64%
Debt-equity ratio	37.92%	42.81%	45.69%

Others

	2023	2022	2021
Tax Expense Rate	12.43%	13.89%	11.69%

EDWARDS LIFESCIENCES CORP

ISIN: US28176E1082 WKN: 28176E108 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	6,004,800,000	5,382,400,000	5,232,500,000
Net income	1,402,400,000	1,521,900,000	1,503,100,000
EBIT	1,414,636,300	1,598,991,950	1,554,699,300
Operating income before taxes	1,598,100,000	1,767,400,000	1,702,000,000
Cash Flow	895,800,000	1,218,200,000	1,732,100,000
Net interest income	42,700,000	9,300,000	-7,400,000
Research and development expenses	1,071,800,000	945,200,000	903,100,000
Income taxes	198,700,000	245,500,000	198,900,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	275,827	282,965	303,118

Board of Directors

Members of Management Board		
Nicholas Valeriani	Chairman of Board of Directors	
David Feinberg	Member of Board of Directors	
Kieran Gallahue	Member of Board of Directors	
Leslie Davis	Member of Board of Directors	
Leslie Heisz	Member of Board of Directors	
Paul LaViolette	Member of Board of Directors	
Ramona Sequeira	Member of Board of Directors	
Steven Loranger	Member of Board of Directors	
Arnold A. Pinkston	Member of Executive Committee	
Bernard J. Zovighian	Member of Executive Committee	
Catherine M. Szyman	Member of Executive Committee	
Christine Z. McCauley	Member of Executive Committee	
Daveen Chopra	Member of Executive Committee	
Dirksen J. Lehman	Member of Executive Committee	
Donald E. Bobo, Jr.	Member of Executive Committee	
Gary I. Sorsher	Member of Executive Committee	
Jean-Luc Lemercier	Member of Executive Committee	
Joseph Nuzzolese	Member of Executive Committee	
Larry L. Wood	Member of Executive Committee	
Scott B. Ullem	Member of Executive Committee	
Todd J. Brinton	Member of Executive Committee	
Wayne Markowitz	Member of Executive Committee	